

22. The polypeptide of claim 20 or 21, wherein said polypeptide is bound to a solid support.

Sub  
B2

23. A method of purifying the autotaxin polypeptide of claim 20 or 21, comprising the steps of:

- i) collecting and concentrating supernatant from cultured A2058 human melanoma cells whereby a first preparation of said polypeptide is produced;
- ii) salt fractionating said first preparation to produce a second polypeptide preparation;
- iii) isolating said polypeptide from said second preparation so that said polypeptide is obtained in substantially pure form.

A1  
Cmcd

24. The method of claim 23, wherein said isolating step is effected by column chromatography.

Sub B3

25. A recombinant autotaxin polypeptide according to claim 20 or 21.

### REMARKS

Applicants respectfully request favorable consideration of the present application and claims. Early and favorable action by the Examiner is earnestly solicited.

No additional fee is believed to be necessary.

The Commissioner is hereby authorized to charge any additional fees which may be required for this amendment, or credit any overpayment to Deposit Account No. 13-4500, Order No. 2026-4149US4.

In the event that an extension of time is required, or which may be required in addition to that requested in a petition and for an extension of time, the Commissioner is

requested to grant a petition for that extension of time which is required to make this response timely and is hereby authorized to charge any fee for such an extension of time or credit any overpayment for an extension of time to Deposit Account No. 13-4500, Order No. 2026-4149US4. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: January 17, 2000

By: 

Dorothy R. Auth

Registration No. 36,434

MORGAN & FINNEGAN  
345 Park Avenue  
New York, New York 10154  
(212) 758-4800  
(212) 751-6849 Telecopier